Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Wim Wuyts et al.|The Lancet Respiratory Medicine|2020Cited by 558
Idiopathic Pulmonary Fibrosis (IPF): An OverviewShaney Barratt, Nazia Chaudhuri|Journal of Clinical Medicine|2018Cited by 378
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 studyJoshua J. Solomon, Marilyn K. Glassberg, Sonye K. Danoff et al.|The Lancet Respiratory Medicine|2022Cited by 211
A Randomized, Embedded, Multifactorial Adaptive Platform trial for ILD (REMAP-ILD): The conceptual designTejaswini Kulkarni, Gísli Jenkins, Kerri A. Johannson et al.|Unknown|2023Cited by 2